Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006386 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00006386 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 80 participants.
The verdict
NCT00006386, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by carmustine in treating patients who have supratentorial glioblastoma multiforme.
Interventions
- RADIATION radiation therapy
- DRUG carmustine
- RADIATION stereotactic radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-03 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006386
The ClinicalTrials.gov registry entry for NCT00006386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which radiation therapy is the first listed.
NCT00006386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006386 about?
NCT00006386 is a clinical study titled "Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by carmustine in treating patient...
What is the current status of trial NCT00006386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2001-03. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00006386?
The interventions under investigation include: radiation therapy (RADIATION), carmustine (DRUG), stereotactic radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT00006386?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.